Keywords: اودنافیل; Erectile Dysfunction; Phosphodiesterase Type 5 Inhibitors; Udenafil; Long Term
مقالات ISI اودنافیل (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: اودنافیل; testis; spermatic cord torsion; reperfusion injury; sildenafil; udenafil; I/R; ischemia and reperfusion; MDA; malondialdehyde; NO; nitric oxide; PDE5; phosphodiesterase-5; T/D; testicular torsion and detorsion; T-SH; total sulfhydryl;
Liver, Pancreas and Biliary TractThe phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-study
Keywords: اودنافیل; Liver cirrhosis; Phosphodiesterase-5-inhibitors; Portal hypertension; Portal pressure; Udenafil;
Efficacy of Once-Daily Administration of Udenafil for 24 Weeks on Erectile Dysfunction: Results from a Randomized Multicenter Placebo-Controlled Clinical Trial
Keywords: اودنافیل; Udenafil; Phosphodiesterase 5 Inhibitors; Clinical Trial; Erectile Dysfunction
Development of udenafil-loaded microemulsions for intranasal delivery: In vitro and in vivo evaluations
Keywords: اودنافیل; Udenafil; Microemulsion; Intranasal delivery; Erectile dysfunction;
Efficacy and Safety of Once-Daily Dosing of Udenafil in the Treatment of Erectile Dysfunction: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Keywords: اودنافیل; Udenafil; Phosphodiesterase type 5 inhibitor (PDE5-I); Erectile dysfunction (ED); Clinical study; Once-daily dosing
Phosphodiesterase Type 5 Inhibitors in the Management of Non-neurogenic Male Lower Urinary Tract Symptoms: Critical Analysis of Current Evidence
Keywords: اودنافیل; Lower urinary tract symptoms; Benign prostatic hyperplasia; Bladder neck; PDE receptors; Phosphodiesterase inhibitors; Cavernous tissue; Erectile dysfunction; Sildenafil; Vardenafil; Tadalafil; Udenafil; Alfuzosin; Tamsulosin; UK-369003
Chronic Administration of Udenafil, A Selective Phosphodiesterase Type 5 Inhibitor, Promotes Erectile Function Recovery in an Animal Model of Bilateral Cavernous Nerve Crush Injury
Keywords: اودنافیل; Apoptosis; Cavernous Nerve Crush Injury; Erectile Dysfunction; Sonic Hedgehog; Udenafil;
A Therapeutic Confirmatory Study to Assess the Safety and Efficacy of Zydena® (Udenafil) for the Treatment of Erectile Dysfunction in Male Patients with Diabetes Mellitus
Keywords: اودنافیل; Erectile Dysfunction; Udenafil; Diabetes Mellitus; Pharmacotherapy for Erectile Dysfunction in Men With Diabetes;
Udenafil Enhances the Recovery of Erectile Function and Ameliorates the Pathophysiological Consequences of Cavernous Nerve Resection
Keywords: اودنافیل; Erectile Dysfunction; Cavernous Nerve Resection; Udenafil; Apoptosis; Fibrosis;
Efficacy of Udenafil for the Treatment of Erectile Dysfunction up to 12 Hours after Dosing: A Randomized Placebo-Controlled Trial
Keywords: اودنافیل; Erectile Dysfunction; PDE5; Long-Acting PDE5 Inhibitor; Udenafil; Clinical Trial;
ORIGINAL RESEARCH-ED PHARMACOTHERAPY: The Efficacy and Safety of Udenafil [Zydena] for the Treatment of Erectile Dysfunction in Hypertensive Men Taking Concomitant Antihypertensive Agents
Keywords: اودنافیل; Erectile Dysfunction; Phosphodiesterase 5 Inhibitor; Udenafil; Hypertension;
The Efficacy and Safety of Udenafil, a New Selective Phosphodiesterase Type 5 Inhibitor, in Patients with Erectile Dysfunction
Keywords: اودنافیل; Erectile Dysfunction; PDE5; Udenafil; Clinical Trial;